CPIX 8-K
Cumberland Pharmaceuticals Inc (CPIX)
8-K
2024-05-07
For: 2024-05-07
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
May 7, 2024 (May 7, 2024 )
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices)
(615 ) 255-0068
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On May 7, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cumberland Pharmaceuticals Inc. | ||||||||||||||||||||
Dated: May 7, 2024 | By: | /s/ John Hamm | ||||||||||||||||||
| John Hamm | ||||||||||||||||||||
| Chief Financial Officer | ||||||||||||||||||||
Cumberland Pharmaceuticals Reports First Quarter 2024
Financial Results & Company Update
NASHVILLE, TENNESSEE (Tuesday, May 7, 2024) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its product portfolio of FDA-approved brands delivered combined revenues of $8.5 million during the first quarter of 2024. The company ended the quarter with $82 million in total assets, $54 million in total liabilities and $27 million of shareholders’ equity.
“It has been a steady start to 2024 – and despite some challenges the biopharmaceutical sector is facing in the financial markets amid stubborn inflation and stalled interest rate cuts, we remain optimistic about our industry’s fundamentals and future,” said Cumberland’s CEO, A.J. Kazimi. “We continue to build our portfolio of innovative and differentiated products here at Cumberland, and our resulting, diversified product line has enabled us to weather external challenges while our team remains responsive to the evolving market. We look forward to sharing an update on our brands, pipeline and partnerships, including a number of growth opportunities.”
Recent company developments include:
Caldolor® Special Report
In March 2024, a Special Report was published in Anesthesiology News, General Surgery News and Pharmacy Practice News presenting the growing amount of clinical data supporting the use of Cumberland’s Caldolor (ibuprofen) injection as a standard of care for the treatment of pain and fever in adults, children and infants as young as 3 months of age.
Takeaways from the Special Report include:
•Intravenous ibuprofen results in significant reduction in temperature compared with placebo in adults and with acetaminophen in pediatric patients.
•Administration of the product prior to surgery leads to patients waking up in significantly less postsurgical pain, while also lessening or even eliminating the need for opioids.
•The use of intravenous ibuprofen in the hospital emergency department for acute pain can minimize opioid requirements while achieving significant pain control.
•Caldolor should be considered a foundation for any multimodal pain regimen.
Pain management has become one of the most common health care problems. As this Special Report states, comprehensive multimodal pain regimens have become key in preventing pain and optimizing pain control, while minimizing the need for opioids. A non-steroidal anti-inflammatory drug, such as Caldolor, can provide a cornerstone for many treatment paradigms.
Federal NOPAIN Act
Cumberland expects Caldolor will be eligible for special Medicare reimbursement under the Non-Opioids Prevent Addiction in the Nation Act (the “NOPAIN Act”), which was enacted as part of the Consolidated Appropriations Act of 2023.
The NOPAIN Act requires Medicare to provide separate and more favorable reimbursement for non-opioid products used to manage pain during surgeries conducted in hospital outpatient departments or in ambulatory surgical centers. The NOPAIN Act applies, in part, to products that are indicated to provide analgesia without acting upon the body’s opioid receptors.
The Centers for Medicare & Medicaid Services (“CMS”) requested that manufacturers with potentially applicable non-opioid products submit comments and supporting clinical evidence regarding products that should be eligible for separate payment. Cumberland submitted a comment letter along with the requisite clinical information to the CMS in September 2023 explaining why Caldolor should be included and separately reimbursed. The company now awaits information from CMS regarding the reimbursement status and price for the product.
The Act is scheduled to go into effect in early 2025 and will initially apply to products that are furnished between January 1, 2025 and January 1, 2028.
New Manufacturing & Supplies of Sancuso®
After acquiring U.S. rights to Sancuso, Cumberland successfully completed the transition from Kyowa Kirin in 2023, including the NDA transfer. A new facility was approved by the FDA for Sancuso and, during the first quarter of 2024, Cumberland completed the manufacturing of Cumberland-packaged product there. The company will launch these new supplies this year. Meanwhile, it continues to support the product through its expanded oncology sales division to help cancer patients by addressing certain side effects associated with their chemotherapy treatments.
Vaprisol® Supply Update
Cumberland’s new manufacturing and distribution partner for Vaprisol is providing a special supply of compounded product in support of critically ill patients. The companies await FDA approval for the facility in order to relaunch the brand.
Vaprisol is the first and only intravenously administered vasopressin receptor antagonist. It is used to raise serum sodium levels in hospitalized patients with hyponatremia, the most common electrolyte disorder among such patients.
Clinical Development Pipeline
Cumberland has been evaluating its ifetroban product candidate, a selective thromboxane-prostanoid receptor antagonist, in a series of clinical studies. It has now been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in healthy volunteers and various patient populations.
Cumberland has initiated its newest clinical program in medical centers across the country and enrollment has now begun in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. This FIGHTING FIBROSIS trial is designed to enroll 128 patients in over 20 medical centers of excellence across the United States. Recent studies have shown ifetroban can both prevent and enhance resolution of lung fibrosis in multiple preclinical models.
Patient enrollment is already well underway in its two other company-sponsored Phase II clinical programs evaluating ifetroban in patients with: 1) Systemic Sclerosis, or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) cardiomyopathy associated with Duchenne Muscular Dystrophy, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.
Cumberland’s plan going forward is to complete each of its company-sponsored studies, analyze their final data, announce top-line results and decide on the best development path for the registration of ifetroban, which the company continues to believe has the potential to benefit many patients with orphan diseases that represent unmet medical needs.
FINANCIAL RESULTS
Net Revenue: For the three months ended March 31, 2024, net revenues were $8.5 million.
Net revenue by product for the first quarter of 2024 included $3.2 million for Kristalose®, $1.8 million for Sancuso®, $1.6 million for Vibativ® and $1.5 million for Caldolor®.
Operating Expenses: Total operating expenses for the first quarter were $10.4 million.
Net Income: The net loss for the first quarter of 2024 was $1.9 million, or $0.14 a share.
Adjusted Earnings: Adjusted earnings for the first quarter of 2024 were a loss of $0.6 million, or $0.05 per share. The adjusted earnings calculation does not include the benefit of the $0.5 million cost of goods for Vibativ and Sancuso during the quarter, which were received as part of each product’s acquisition.
Balance Sheet: At March 31, 2024, Cumberland had $82 million in total assets, including $19 million in cash and cash equivalents.
Total liabilities were $54 million, including $16 million outstanding on the company’s revolving line of credit. Total shareholders’ equity was $27 million at the end of the quarter.
EARNINGS REPORT CALL:
A conference call will be held on May 7, 2024, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results. To participate in the call, please register at: https://register.vevent.com/register/BIbb2d35bc9570474dabf8b2e3d2e4ca72.
Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a “Call Me” option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via Cumberland’s website or by visiting https://edge.media-server.com/mmc/p/uqsbkw9t.
ABOUT CUMBERLAND PHARMACEUTICALS:
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company’s portfolio of FDA-approved brands includes:
•Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
•Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
•Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
•Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
•Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
•Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland’s approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company’s website www.cumberlandpharma.com.
About Acetadote® (acetylcysteine) Injection
Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit www.acetadote.com.
About Caldolor® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.
About Kristalose® (lactulose) Oral Solution
Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com.
About Sancuso® (granisetron) Transdermal System
Sancuso is the only skin patch approved by the U.S. Food and Drug Administration for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the SANCUSO patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient’s bloodstream. It can be worn for up to seven days in a row for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.
About Vaprisol® (conivaptan hydrochloride) Injection
Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com.
About Vibativ® (telavancin) for Injection
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com.
ABOUT CUMBERLAND EMERGING TECHNOLOGIES:
Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN and WinHealth. The mission of CET is to advance biomedical technologies and products conceived at Vanderbilt University and other regional research centers toward the marketplace.
CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET’s Life Sciences Center provides laboratory space, equipment and infrastructure for CET’s activities and other early-stage life sciences ventures.
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company’s intent, belief or expectations, and can be identified by the use of terminology such as “may,” “will,” “expect,” “believe,” “intend,” “plan,” “estimate,” “should,” “seek,” “anticipate,” “look forward” and other comparable terms or the negative thereof. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland’s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company’s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (“SEC”), as well as the company’s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE: Cumberland Pharmaceuticals Inc.
Investor Contact: | Media Contact: | ||||
Shayla Simpson | Molly Aggas | ||||
Cumberland Pharmaceuticals Inc. | Dalton Agency | ||||
(615) 255-0068 | (704) 641-6641 | ||||
- MORE -
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(Unaudited)
| March 31, 2024 | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 18,548,485 | $ | 18,321,624 | |||||||
| Accounts receivable, net | 10,647,267 | 9,758,176 | |||||||||
| Inventories, net | 4,327,526 | 4,609,362 | |||||||||
| Prepaid and other current assets | 2,682,673 | 3,025,248 | |||||||||
| Total current assets | 36,205,951 | 35,714,410 | |||||||||
| Non-current inventories | 12,915,896 | 12,804,529 | |||||||||
| Property and equipment, net | 369,499 | 367,903 | |||||||||
| Intangible assets, net | 21,522,441 | 22,607,918 | |||||||||
| Goodwill | 914,000 | 914,000 | |||||||||
| Operating lease right-of-use assets | 6,521,088 | 6,674,394 | |||||||||
| Other assets | 3,060,643 | 2,692,921 | |||||||||
| Total assets | $ | 81,509,518 | $ | 81,776,075 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 13,075,764 | $ | 14,037,629 | |||||||
| Operating lease current liabilities | 362,244 | 348,092 | |||||||||
| Other current liabilities | 12,987,372 | 13,596,528 | |||||||||
| Total current liabilities | 26,425,380 | 27,982,249 | |||||||||
| Revolving line of credit | 16,084,144 | 12,784,144 | |||||||||
| Operating lease non-current liabilities | 5,200,148 | 5,296,247 | |||||||||
| Other long-term liabilities | 6,610,294 | 6,453,566 | |||||||||
| Total liabilities | 54,319,966 | 52,516,206 | |||||||||
| Equity: | |||||||||||
| Shareholders’ equity: | |||||||||||
Common stock—no par value; 100,000,000 shares authorized; 14,159,954 and 14,121,833 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 46,923,757 | 47,091,602 | |||||||||
| Accumulated deficit | (19,434,424) | (17,488,161) | |||||||||
| Total shareholders’ equity | 27,489,333 | 29,603,441 | |||||||||
| Noncontrolling interests | (299,781) | (343,572) | |||||||||
| Total equity | 27,189,552 | 29,259,869 | |||||||||
| Total liabilities and equity | $ | 81,509,518 | $ | 81,776,075 | |||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
| Three months ended March 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Net revenues | $ | 8,497,701 | $ | 9,224,638 | |||||||
| Costs and expenses: | |||||||||||
| Cost of products sold | 1,575,542 | 1,250,264 | |||||||||
| Selling and marketing | 4,154,588 | 4,277,318 | |||||||||
| Research and development | 1,158,253 | 1,499,670 | |||||||||
| General and administrative | 2,367,907 | 2,498,993 | |||||||||
| Amortization | 1,110,661 | 1,230,071 | |||||||||
| Total costs and expenses | 10,366,951 | 10,756,316 | |||||||||
| Operating loss | (1,869,250) | (1,531,678) | |||||||||
| Interest income | 96,746 | 50,190 | |||||||||
| Other income | — | 1,847,065 | |||||||||
| Interest expense | (118,526) | (186,353) | |||||||||
| Income (loss) before income taxes | (1,891,030) | 179,224 | |||||||||
| Income tax expense | (11,442) | (6,938) | |||||||||
| Net income (loss) | (1,902,472) | 172,286 | |||||||||
| Net income (loss) at subsidiary attributable to noncontrolling interests | (43,791) | 19,898 | |||||||||
| Net income (loss) attributable to common shareholders | $ | (1,946,263) | $ | 192,184 | |||||||
| Earnings (loss) per share attributable to common shareholders | |||||||||||
| - basic | $ | (0.14) | $ | 0.01 | |||||||
| - diluted | $ | (0.14) | $ | 0.01 | |||||||
| Weighted-average shares outstanding | |||||||||||
| - basic | 14,098,022 | 14,359,322 | |||||||||
| - diluted | 14,098,022 | 14,587,843 | |||||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Three months ended March 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net income (loss) | $ | (1,902,472) | $ | 172,286 | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization expense | 1,150,685 | 1,255,675 | |||||||||
| Amortization of operating lease right-of-use assets | 285,184 | 172,209 | |||||||||
| Share-based compensation | 78,754 | 90,156 | |||||||||
| Decrease in non-cash contingent consideration | (230,430) | (267,637) | |||||||||
| Increase in cash surrender value of life insurance policies over premiums paid | (129,217) | (30,799) | |||||||||
| Increase in noncash interest expense | 3,810 | 4,296 | |||||||||
| Gain on receivable of FDA fees | — | (1,847,065) | |||||||||
| Net changes in assets and liabilities affecting operating activities: | |||||||||||
| Accounts receivable | (1,066,410) | 481,613 | |||||||||
| Inventories | 170,469 | (323,557) | |||||||||
| Other current assets and other assets | 205,619 | 383,612 | |||||||||
| Operating lease liabilities | (213,825) | 127,137 | |||||||||
| Accounts payable and other current liabilities | (645,542) | (1,105,263) | |||||||||
| Other long-term liabilities | 156,728 | (530,872) | |||||||||
| Net cash used in operating activities | (2,136,647) | (1,418,209) | |||||||||
| Cash flows from investing activities: | |||||||||||
| Additions to property and equipment | (41,621) | (107,260) | |||||||||
| Additions to intangible assets | (16,565) | (67,193) | |||||||||
| Net cash used in investing activities | (58,186) | (174,453) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Borrowings on line of credit | 11,000,000 | 8,000,000 | |||||||||
| Payments on line of credit | (7,700,000) | (8,127,714) | |||||||||
| Cash settlement of contingent consideration | (630,701) | (1,464,311) | |||||||||
| Payments made in connection with repurchase of common shares | (247,605) | (187,117) | |||||||||
| Net cash provided by (used in) financing activities | 2,421,694 | (1,779,142) | |||||||||
| Net increase (decrease) in cash and cash equivalents | 226,861 | (3,371,804) | |||||||||
| Cash and cash equivalents at beginning of period | $ | 18,321,624 | $ | 19,757,970 | |||||||
| Cash and cash equivalents at end of period | $ | 18,548,485 | $ | 16,386,166 | |||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Reconciliation of Net Income (loss) Attributable to Common Shareholders to Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share
(Unaudited)
| Three months ended March 31, | Three months ended March 31, | |||||||||||||||||||||||||
| 2024 | 2024 | 2023 | 2023 | |||||||||||||||||||||||
| Earnings impact | Earnings per share impact | Earnings impact | Earnings per share impact | |||||||||||||||||||||||
| Net income (loss) attributable to common shareholders | $ | (1,946,263) | $ | (0.14) | $ | 192,184 | $ | 0.01 | ||||||||||||||||||
| Less: Net income (loss) at subsidiary attributable to noncontrolling interests | (43,791) | — | 19,898 | — | ||||||||||||||||||||||
| Net income (loss) | (1,902,472) | (0.13) | 172,286 | 0.01 | ||||||||||||||||||||||
| Adjustments to net loss | ||||||||||||||||||||||||||
| Income tax expense | 11,442 | — | 6,938 | — | ||||||||||||||||||||||
| Depreciation and amortization | 1,150,685 | 0.08 | 1,255,675 | 0.09 | ||||||||||||||||||||||
Share-based compensation (a) | 78,754 | 0.01 | 90,156 | 0.01 | ||||||||||||||||||||||
| Interest income | (96,746) | (0.01) | (50,190) | — | ||||||||||||||||||||||
| Interest expense | 118,526 | 0.01 | 186,353 | 0.01 | ||||||||||||||||||||||
| Adjusted Earnings (Loss) and Adjusted Diluted Earnings (Loss) Per Share | $ | (639,811) | $ | (0.05) | $ | 1,661,218 | $ | 0.11 | ||||||||||||||||||
| Diluted weighted-average common shares outstanding: | 14,098,022 | 14,587,843 | ||||||||||||||||||||||||
The Company provided the above adjusted supplemental financial performance measures, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The definition of these supplemental measures may differ from similarly titled measures used by others.
Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company's reported results of operations, management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Cumberland's management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company's operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company's operating results. Management believes that presenting these supplemental measures provides useful information about the Company's underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company's operating performance.
The Company defines these supplemental financial measures as follows:
•Adjusted Earnings (loss): net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense. The definition of Adjusted Earnings has been changed to include all gains and losses, as gains are occurring more frequently for the Company.
(a) Represents the share-based compensation of Cumberland.
•Adjusted Diluted Earnings (loss) Per Share: Adjusted Earnings (loss) divided by diluted weighted-average common shares outstanding.